Novozymes A/S
| Date: | 11 Feb 2022 |
|---|---|
| Country: | Denmark |
| Customer: | Novozymes A/S |
| Amount in DKK: | DKK 750 million |
| Amount in EUR: | EUR 100.8 million |
| Maturity: | 10 years |
| Business sector: | Connectivity & Consumer |
Project
The loan will finance Novozymes research and development (R&D) activities in 2021.
The project includes R&D activities in consumer biosolutions as well as agriculture and industrial biosolutions.
Approximately 13% of Novozymes’ revenue is reinvested in research annually. The company holds more than 6,500 active and pending patents and launches 15-20 new products every year.
This is NIB’s sixth loan agreement for Novozymes R&D investments.
Novozymes is a global biotechnology company with a strong focus on enzyme production. The company’s biosolutions cover a wide range of applications from the removal of trans-fats in food to advancements in renewable energy sources. Novozymes employs over 6,100 people globally, more than 20% of whom work with R&D activities.
Fulfilment of NIB's mandate
The project is the continuation of Novozymes’ R&D programme, enhancing the product and process development of the company.
The latest investments will strengthen Novozymes’ market leading portfolio in agriculture, animal health and nutrition, grain and tech processing as well as bioenergy solutions. It will also ensure better quality and more efficient production for their household care, food, beverages, and human health products.
The company has a long list of collaborations with both corporates and academic institutions. R&D investments are likely to have positive spill-over effects on other companies operating in the industry and in the region.
Impact indicators:
- R&D intensity (R&D expenditures as a % of turnover): 13-14%
Sustainability summary
No significant environmental risks identified in relation to Novozymes’ R&D projects.
